Reckitt Benckiser Group (OTCMKTS:RBGLY) Stock Rating Lowered by Barclays

Reckitt Benckiser Group (OTCMKTS:RBGLY) was downgraded by equities research analysts at Barclays from an “overweight” rating to an “equal weight” rating in a research note issued on Tuesday, Marketbeat reports.

Several other research analysts have also recently commented on RBGLY. Sanford C. Bernstein cut Reckitt Benckiser Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 4th. HSBC raised shares of Reckitt Benckiser Group from a “hold” rating to a “buy” rating in a report on Wednesday, December 11th. Finally, Hsbc Global Res raised shares of Reckitt Benckiser Group from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy”.

Reckitt Benckiser Group Stock Performance

RBGLY opened at $13.23 on Tuesday. Reckitt Benckiser Group has a 12-month low of $10.24 and a 12-month high of $15.03. The stock’s 50 day moving average price is $12.31 and its two-hundred day moving average price is $12.03. The company has a quick ratio of 0.47, a current ratio of 0.69 and a debt-to-equity ratio of 0.97.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.